Keep Antibiotics Working (KAW) is on the Food and Drug Administration’s (FDA) case again about the growth promotion marketing loophole for antibiotics.
Last May, KAW alerted FDA to their concerns that drug manufacturer Novartis was using promotional materials for a feed additive used to treat dysentery and pneumonia and enteric disease in pigs that spoke more to production issues than animal health. FDA told the coalition via email that they had discussed the issue with Novartis, but the agency would not reveal any details about the substance of their conversation.
In June, KAW noticed that the company had modified the drug’s marketing page for the better, but the coalition didn’t think the changes were adequate. They met with FDA in July to explain their overall concerns and to ask the agency to clarify that this type of advertising would not be tolerated.
No comments:
Post a Comment